Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. by Gazet, J. C. et al.
British Journal of Cancer (1996) 73, 758-762
fw (C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Assessment of the effect of pretreatment with neoadjuvant therapy on
primary breast cancer
J-C Gazet, RC Coombes, HT Ford, M Griffin, C Corbishley, V Makinde, S Lowndes, J Quilliam
and R Sutcliffe
Breast Research Unit, St. George's Hospital, London SWJ7, UK.
Summary Patients with invasive cancer of the breast (TI-4, NO-2, MO) were assigned to pretreatment based
on oestrogen receptor (ER) status; patients with ER-negative tumours received chemotherapy [mitozantrone,
methotrexate and mitomycin C (MMM)] for 3 months, patients with ER-positive tumours underwent
endocrine therapy [luteinising hormone releasing hormone (LHRH) agonist goserelin (leuprolide-
premenopausal) or 4-hydroxyandrostenedione (formestane-post-menopausal)] for 3 months. Of the first 100
patients assessed at 3 months, 47 with ER-positive tumours had a 40.4% response (premenopausal 53.8%;
post-menopausal 35%) and 53 with ER-negative tumours had a 60% response (premenopausal 57%; post-
menopausal 63%). Patients with early breast cancer (TI/T2) had a complete clinical resolution in 41% (16/39)
of cases after MMM and in 20% (7/35) of cases following endocrine therapy compared with 14% (2/14)
advanced tumours (T3/T4) following MMM and (0/12) following endocrine therapy. However, in those
patients achieving a complete clinical response, subsequent appropriate surgery showed that 16 of 19 patients
(84%) had evidence of residual viable tumour on histological examination.
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Previous studies have demonstrated the excellent reduction in
size of primary breast cancer achieved by chemotherapy
(Delena et al., 1981; Swain et al., 1987; Perloff et al., 1988)
and endocrine therapy (Smith et al., 1993, Forrest et al.,
1986).
A randomised trial of primary chemotherapy in patients
with advanced primary breast carcinoma has shown that it is
more effective in rapidly reducing the size of the primary
lesion than endocrine therapy (P=0.001) and that it
significantly alters the future management of these patients
(Gazet et al., 1991). Despite screening, a high proportion of
patients still present with T3 or T4 breast carcinoma
requiring mastectomy. For this reason we have evaluated
the role of neoadjuvant therapy with particular regard to the
role of oestrogen receptor (ER) determination by immuno-
cytochemistry using oestrogen receptor immunocytochemical
assay (ERICA) as in those patients in which the ER was not
evaluated before treatment only 10% responded to endocrine
therapy (Gazet et al., 1991).
We hypothesised that endocrine therapy might have a role
in neoadjuvant therapy of breast cancer, provided that the
ERICA could be performed in the primary tumours, thus
indicating which tumours were hormone sensitive.
Patients, materials and methods
This trial included a series of consecutive patients aged
between 30 and 69 (mean 54.02) attending the Combined
Breast Clinic at St. George's Hospital between 1990 and 1993
who had a clinical carcinoma of the breast, T -T4 NO, NI
or N2. This was confirmed by mammographic and fine needle
aspiration cytology (FNAC) with no evidence of metastases
on standard screening (Coombes et al., 1980), which included
chest radiograph, bone scan, liver ultrasound, full blood
picture and liver function tests.
All patients were fully informed of the object of the trial.
Those joining the trial gave written consent in every case
according to the Helsinki agreement. The patients then had a
preliminary Trucut biopsy of the tumour to confirm the
presence of an invasive ductal or lobular carcinoma. All other
malignant tumours including non-invasive carcinoma, ductal
breast carcinoma in situ (DCIS) and lobular breast carcinoma
in situ (LCIS), were excluded from the trial.
Those patients who on Trucut biopsy had an ER-positive
invasive carcinoma (more than 30% of carcinoma cells
staining for ERICA) received endocrine treatment; premeno-
pausal-leuprorelin [a luteinising hormone releasing hormone
(LHRH) agonist leuprolide] 3.75 mg subcutaneously every 4
weeks; or post-menopausal-4-hydroxyandrostenedione (for-
mestane), 250 mg i.m. every 2 weeks. Those patients who were
ER negative on Trucut biopsy received chemotherapy;
MMM-mitozantrone 7 mg m-2, every 3 weeks, mitomycin
C 7 mg m-2 every 6 weeks, methotrexate 30 mg m-2 every 3
weeks with folinic acid rescue 15 mg 4-6 hourly, six doses
starting 24 h after infusion; four courses in 3 months
(12 weeks).
All patients were clinically assessed at 4 weekly intervals.
Tumour size was measured with calipers accurately by
bidimensional measurements and the area calculated as the
sum of these two measurements. All patients had a
preliminary mammogram before treatment and a second
mammogram 12 weeks before definitive surgery and radio-
therapy. A peripheral blood count was performed 21 days
before each course of chemotherapy. Nadir counts (day 10-
14) were not performed. All responses were assessed
according to standard UICC criteria and toxicity according
to WHO grading.
At 3 months, following clinical and investigative reassess-
ment, which included mammography and full standard
screening, those patients treated by primary chemotherapy
or endocrine therapy received appropriate surgery and/or
radiotherapy depending on the post-treatment clinical TNM
staging.
Results
Of the first 100 patients assessed at 3 months, 47 had ER-
positive tumours and therefore received endocrine therapy
according to their menopausal status. The clinical response
rate was 53.8% in the premenopausal patients compared with
35% in the post-menopausal patients. In the smaller tumours
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(TI, T2) there was a clinical response rate of 34% in post-
menopausal women compared with 66% in premenopausal
women. In the larger tumours (T3, T4) there was no
significant difference in the response between premenopausal
patients (25%) and post-menopausal patients (37%). How-
ever, in each group the numbers are too small to allow valid
statistical assessment.
A total of 53 patients had an ER-negative tumour and,
irrespective of menopausal status, had chemotherapy. The
clinical response rate to MMM chemotherapy was 60% with
a complete clinical response rate of 34%. The clinical
response rate in the smaller tumours (TI, T2) was 69% as
compared with 35% in the larger tumours (T3, T4). The
clinical response rate in the premenopausal women was 57%
compared with 63% in the post-menopausal women.
Considering all the patients with early breast cancer only
(T1,T2), there was a complete clinical response in 41% (16/
39) on MMM. This compared with only 2/14 (14%) in the
T3/T4 carcinomas. These results contrast with the endocrine
therapy, in which no complete clinical response was seen in
the T3/T4 group. Including all cases (TI-T4) the complete
regression rate was lower but the overall response rate was
good: 60% for MMM, 35% for formestane, and 53.8% for
leuprolide (Table I). In the group T1/T2, 86% (62) had a
wide local excision, 3% (two) had a mastectomy and 11%
(eight) were treated by radiotherapy. In the T3/T4 group,
42% (11) had a wide local excision, 35% (nine) had a
mastectomy and 23% (six) were treated by radiotherapy.
There were two treatment violations.
Histological assessment after treatment
A detailed study of the histopathological changes associated
with pretreatment has been made and will be reported
elsewhere (Corbishley et al., 1996). Ofparticular interest were
the changes observed in 19 of the 25 patients who were
considered clinically to have shown a complete response. Six
had refused surgery and proceeded to radiotherapy.
The initial Trucut biopsy specimens were compared with
the post treatment localisation biopsies. When assessable, the
morphology of the post treatment tumour closely matched
the pretreatment biopsy for both histological type and grade
of tumour.
The post-therapy breast tissue specimens were X-rayed
with the localisation wire in situ, serially sliced at 4 mm
intervals and extensively sampled. Sixteen showed invasive
carcinoma (Figure 1). In three patients no residual tumour
cells were identified (Figure 2). Seven patients showed foci of
invasive tumour less than 10 mm in maximum dimensions
(range 1-8 mm) (Figure 3). The remaining nine patients
showed tumour masses ranging from 10 to 70 mm. The
largest residual tumour mass was a widely infiltrating lobular
carcinoma with no histological evidence of tumour regression
(Figure 4). Two patients with proven invasive ductal
carcinoma on Trucut biopsy showed residual widespread
ductal carcinoma in situ only (35 mm and 25 mm respec-
tively) (Figure 5).
In all, 78 post treatment specimens were available for
tumour assessment. There were two violations, six refused
surgery and 14 were treated by radiotherapy (Table II).
In those patients showing histological evidence of tumour
Figure 1 Frozen section of Trucut biopsy showing invasive
ductal carcinoma (x 70, haematoxylin and eosin).
Figure 2 Focal area of scarring containing only macrophages
and other inflammatory cells in patient with complete histological
response (x 70, haematoxylin and eosin).
Figure 3 Microscopic focus of viable malignant cells in patient
with clinical complete response (x 70, haematoxylin and eosin).
Table I Clinial assessment at 12 weeks of patients receiving endocrine or chemotherapy
MMM Leuprolide Formestane
No. of patient 53 13 34
T-stage T1/2 T3/4 T1/2 T3/4 T1/2 T3/4
Menopause status Pre Post Pre Post Pre Post
CR 8 8 1 1} 60%a 2 O} 53.8%b 5 0} 35%C
PR 3 8 3 0} 0 1} 4 3}
NC 6 3 4 2 1 3 11 2
PD 1 2 0 3 2 0 6 3
Complete response rate: '34%, 15%, C14.7%. CR, complete response; PR, partial response; NC, no change, PD, progressive disease.Primary breast cancer and neoadjuvant therapy pretreatment
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regression there were aggregates of foamy and haemosiderin-
laden macrophages with stromal fibrosis, elastosis and
microcalcification. In some cases there was a pronounced
inflammatory cell infiltrate. Immunohistochemical positivity
with antibodies to cytokeratin (CAM 5.2) and epithelial
membrane antigen (EMA) was helpful in the identification of
small foci of residual tumour. All patients had histological
assessment of axillary lymph nodes and only two patients
showed lymph node metastases (11.7%) (Table III).
Figure 4 Widespread invasive lobular carcinoma in patient with
clinical complete response (x 70, haematoxylin and eosin).
Figure 5 Persistent ductal carcinoma in situ in patient with
complete clinical response (x 45, haematoxylin and eosin).
Table II Histological assessment of tumour type in patients
undergoing surgery following endocrine therapy or chemotherapy
Tumour type MMM Leu/4HAD
No residual tumour 3 1
DCIS only 2 0
Microinvasion 0 1
Invasive ductal
Grade I 3 4
Grade II 17 18
Grade III 10 5
Invasive lobular 1 6
Special type
Tubular 1 2
Cribriform 1 1
Collid 1 0
Other 1 0
Total 40/53 38/47
Toxicity
As anticipated, more subjective side-effects were experienced
with MMM chemotherapy than endocrine therapy (Tables IV
and V). The most severe were alopecia and gastrointestinal
disturbance. Eleven per cent (6/53) suffered neutropenia
grades I and II but not severe enough to reduce drug dose
administration or perform nadir counts. The most common
toxic effects of endocrine therapy have been those associated
with oestrogen deprivation such as hot flushes (5/47), with
alopecia and gastrointestinal disturbance contributing to the
rest. None warranted stopping treatment (Tables IV and V).
Table m Histological changes noted post treatment with endo-
crine or chemotherapy
Changes MMM Endocrine
Fibrosis
None 3 1
Mild 10 25
Moderate 25 12
Marked 2 1
Lymphocytic infiltrate:
Peritumoral 25 17
None 14 21
Mild 1 0
Moderate 0 0
Marked
Lymphocytic infiltrate:
In tumour 9 14
None 20 18
Mild 10 6
Moderate 1 0
Marked
Haemosiderin
None 21 35
Mild 11 I
Moderate 6 1
Marked 2 1
Table IV Chemotherapy toxicity in 53 patients receiving MMM
(1993)
Side-effect Grade
I II III IV Total %
Lethargy 4 6 17 13 40 75
Nausea 10 13 7 6 36 67
Alopecia 16 8 4 2 30 56
Stomatitis 15 10 3 3 31 58
Constipation 7 5 4 2 18 33
Vomiting 4 2 4 1 11 20
Diarrhoea 4 1 3 1 9 16
Neutropenia 4 2 0 0 6 11
Oedema 4 1 1 0 6 11
Ataxia 3 2 0 0 5 9
Pyrexia 3 0 0 0 3 5
Skin rash 3 1 1 0 5 9
Neuropathy 2 3 0 0 5 9
Hot flushes 0 0 2 0 2 3
Other 3 6 0 1 10 18
WHO criteria.
Table V Hormone therapy toxicity in 47 patients receiving
formestane or leuprolide
Side-effects Formestane Leuprolide Total %
Hot flushes 1 4 5 10
Other 1 2 3 6
Nausea 1 1 2 4
Vomiting 1 1 2 4
Lethargy 1 1 2 4
Alopecia 2 1 3 6Ps
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The results of the present trial of systemic treatment for
breast cancer based on ER status of the primary tumour as
determined by ERICA on a Trucut are encouraging. Overall,
we observed a complete clinical response rate of 24% at 3
months with a further 28% showing a partial response. The
difference when compared with our original previous study
showing a higher response rate (40% compared with 10%)
seen with primary endocrine therapy, was presumably due to
our ability to select these patients by determining their ER
status. This means that this subgroup of ER-positive patients
can now be spared the toxicity of chemotherapy currently
being given as first-line neoadjuvant therapy.
Owing to ourfamiliarity with MMM regimen, wechose it as
the chemotherapeutic combination for our ER-negative
patients. The chemotherapeutic combination ofmitozantrone,
methotrexate and mitomycin C (3M) was devised as first-line
treatment for disseminated breast cancer in 1987 by Powles et
al. (1991). Subsequent studies have shown that 3M compares
favourably with vincristine, anthracyclines (doxorubicin or
epirubicin) and cyclophosphamide (VA) having significantly
less symptomatic toxicity through greater myelosuppression in
the management ofadvancedbreastcancer(Powles etal., 1991)
and has an efficacy and toxicity spectrum very similar to
cyclophosphamide, methotrexate and 5-fluorouracil (5-FU)
(CMF) (Jodrell et al., 1991).
Leuprolide, an LHRH agonist in premenopausal patients
with a major effect via ovarian suppression (Nicholson et al.,
1985, Dixon et al., 1990) and formestane (4-hydroxyandroste-
nedione), an aromatase inhibitor in oestrogen synthesis in post-
menopausal women (Stein et al., 1990) were used in preference
to tamoxifen in an attempt to facilitate assessment at 3 months,
as tamoxifen, in our experience, can cause tumour flare and
also takes longer to achieve a response (Gazet et al., 1994).
The results of this pilot study suggested that 60% of
patients treated with chemotherapy had a clinical reduction in
the size of their tumour at 12 weeks compared with 44%
receiving endocrine treatment. This is in part due to the well-
documented fact that endocrine treatment will take longer to
be effective and our cut-off point was 3 months (Gazet et al.,
1994). There were two important clinical implications. Firstly,
a significantly greater proportion ofpatients had conservative
surgery. Secondly, the degree of reduction in size achieved by
primary chemotherapy may well reflect the sensitivity of
micrometastases to systemic chemotherapy and thus could be
a highly significant prognostic feature in patients with breast
cancer. This has confirmed the results of previous non-
randomised trials using chemotherapy alone (Hortobagyi et
al., 1991) or with radiotherapy and endocrine therapy (Rubens
et al., 1992). However, although 25 patients (25%) had a
complete clinical resolution of their primary tumour, the
radiological assessment showed an average mammographic
reduction in size by 78% and on ultrasound by 85%.
The importance of the residual mass requires further
interpretation as to its significance (Stein et al., 1990). The
fact that residual tumour was present in 16 of 19 specimens
examined suggests the former, and confirms the importance
of surgical excision and thorough pathological assessment
after neoadjuvant therapy. Six patients who had a complete
clinical response having refused surgery, accepted radio-
therapy treatment to the breast. To date one has had local
recurrence and a mastectomy.
Although the literature on chemotherapy in breast cancer
is extensive there is no report of a randomised trial on
pretreatment with chemotherapy or endocrine therapy on
TI -T4 tumours based on ER status of the primary cancer.
Anderson et al. (1991), in a non-randomised trial of patients
with tumours greater than 4 cm, noted a 39% response (24
61) in patients receiving endocrine therapy only, with one
complete remission, whereas there was a significant
reduction in 72% (34/47) patients receiving CHOP
(cyclophosphamide 1 gm-2, doxorubicin 50 mg m-2, vmcris-
tine 1.4 mg m-2 with oral prednisolone 40 mg per day for 5
days). Thirteen (27.6%) had a complete regression. Others
(Bonadonna et al., 1990) using CMF, 5-FU, FAC or FEC
have shown, in tumours greater than 3 cm, sufficient
regression to avoid mastectomy in 81% of patients (127,
157).
Certainly with tumours 3 cm or larger, primary che-
motherapy with CMF or MMM with radiotherapy reduces
the need for mastectomy to 22% with a further 27% having a
wide local excision (Iveson et al., 1991) and can produce a
potential breast conservation group of 23% after only three
courses of chemotherapy with VAC (Singletary et al., 1992).
Ragaz et al. (1992) have suggested that in stage HII breast
cancer treatment with chemotherapy (doxorubicin, cyclopho-
sphamide, methotrexate and 5-FU) and radiotherapy
preoperatively will have a substantial reduction of patholo-
gically involved lymph nodes at mastectomy and that such
downstaging may be associated with a survival advantage, to
be confirmed by a randomised trial.
In premenopausal women with advanced breast cancer
LHRH agonists will reduce serum oestradiol levels to the
equivalent of the menopause or surgical oophorectomy
(Dixon et al., 1990). These agents have an indirect action
by reducing peripheral hormones rather than acting directly
on LHRH receptors on the tumour (Harris et al., 1989).
Toxicity has been limited to hot flushes on either 3.75 or
7.5 mg i.m.i., once every 4 weeks (Dowsett et al., 1990). In
post-menopausal patients the response to LHRH agonists has
varied from no objective response (Crighton et al., 1989) to
20% (Plowman et al., 1986).
From its first use in 1984 (Coombes et al., 1984),
formestane has been an effective agent in post-menopausal
patients with breast cancer and far more effective than
aminoglutethmide. Reports have suggested a 27% response
and 19% stabilisation in advanced breast cancer (Goss et al.,
1986). The median remission was 12 months in 33% of
patients (14) and stabilisation in a further 14%. Ninety per
cent of patients suffered no side-effects (Cunningham et al.,
1987) and the drug is effective by both the intramuscular
(Goss et al., 1986) and oral routes (Cunningham et al., 1987).
For all these reasons we chose formestane as the treatment
for post-menopausal patients in this study. A recent study of
post-menopausal women with advanced breast cancer
(Mauriac et al., personal communication), in which more
than 400 patients were randomised to received either
tamoxifen or formestane, has shown similar response rates
of side-effects in both arms of the study.
Thus, in conclusion, there is strong evidence that
appropriate pretreatment of breast cancer with chemother-
apy or endocrine therapy according to the oestrogen receptor
status will downgrade the tumour, increasing the opportunity
for more conservative surgery.
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